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Abstract
Objective To assess the influence of trial sample size on treatment
effect estimates within meta-analyses.
Design Meta-epidemiological study.
Data sources 93 meta-analyses (735 randomised controlled trials)
assessing therapeutic interventions with binary outcomes, published in
the 10 leading journals of each medical subject category of the Journal
Citation Reports or in the Cochrane Database of Systematic Reviews.
Data extraction Sample size, outcome data, and risk of bias extracted
from each trial.
Data synthesis Trials within each meta-analysis were sorted by their
sample size: using quarters within each meta-analysis (from quarter 1
with 25% of the smallest trials, to quarter 4 with 25% of the largest trials),
and using size groups across meta-analyses (ranging from <50 to ≥1000
patients). Treatment effects were compared within each meta-analysis
between quarters or between size groups by average ratios of odds
ratios (where a ratio of odds ratios less than 1 indicates larger effects
in smaller trials).
Results Treatment effect estimates were significantly larger in smaller
trials, regardless of sample size. Compared with quarter 4 (which included
the largest trials), treatment effects were, on average, 32% larger in
trials in quarter 1 (which included the smallest trials; ratio of odds ratios
0.68, 95% confidence interval 0.57 to 0.82), 17% larger in trials in quarter
2 (0.83, 0.75 to 0.91), and 12% larger in trials in quarter 3 (0.88, 0.82 to
0.95). Similar results were obtained when comparing treatment effect
estimates between different size groups. Compared with trials of 1000
patients or more, treatment effects were, on average, 48% larger in trials
with fewer than 50 patients (0.52, 0.41 to 0.66) and 10% larger in trials
with 500-999 patients (0.90, 0.82 to 1.00).
Conclusions Treatment effect estimates differed within meta-analyses
solely based on trial sample size, with stronger effect estimates seen in
small to moderately sized trials than in the largest trials.
Introduction
Sample size varies greatly among trials, ranging from tens of
patients to thousands of patients,1 even within a meta-analysis
investigating the same question. For example, a meta-analysis
in cardiology2 included trials with sizes ranging from 62 patients
to 45 852 patients. Our knowledge about the influence of trial
sample size on treatment effect estimates is based on the small
study effect—the tendency for small trials to report greater
treatment benefits than large trials in the same meta-analysis.3-5
A study based on a collection of meta-analyses in osteoarthritis
showed that trials including fewer than 100 patients per arm
yielded, on average, greater treatment effect estimates than did
larger trials.6
The concept of a single threshold to distinguish small trials from
large trials, whatever the medical area or intervention being
tested, is not straightforward.7 For binary outcomes, the required
sample size depends on the magnitude of treatment effect as
well as the number of events and frequency of the medical
condition. Therefore, a trial of 1000 patients can be considered
large for certain medical conditions and small for others.
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In this study, we assessed the influence of trial sample size on
treatment effect estimates in a large collection of meta-analyses
of various medical conditions and interventions.
Methods
Data sources
This study combined data from two independent collections of
meta-analyses of randomised controlled trials assessing
therapeutic interventions with binary outcomes. The first
collection included 48 meta-analyses (421 trials) published in
the 10 leading journals of each medical subject category of the
Journal Citation Reports during two periods: between July 2008
and January 2009 and between January and June 2010 or in
issue 4 of the Cochrane Database of Systematic Reviews in
2008. Further details about the search strategy and selection of
meta-analyses have been published.8 Reports of all component
trials from included meta-analyses were obtained.
The second collection included 45 meta-analyses (314 trials)
published in the Cochrane Database of Systematic Reviews
between January and July 2011. We included meta-analyses
assessing a binary outcome for the primary or main outcome
measure and involving four or more trials. If the meta-analysis
reported combined results for more than one primary binary
outcome, we selected the first reported outcome if it was
described in enough trial reports. We excluded meta-analyses
that overlapped with the first collection. Web appendix 1
includes details of the selection process for both collections.
Data extraction and risk of bias assessment
Using a standardised data extraction form, we extracted the
following data for each randomised controlled trial: the date of
publication, whether the trial was a single centre or multicentre
trial (with at least two different centres), the number of patients
with the outcome in each group, and the number of patients
randomised in each group. Data for risk of bias were also
collected by using the following domains of the risk of bias tool
of the Cochrane Collaboration9 10: methods for sequence
generation and allocation concealment, blinding, and incomplete
outcome data. Each domain was rated as having low, high, or
unclear risk of bias, according to the recommendations of the
Cochrane Collaboration.9 10 For each trial, the overall risk of
bias was classified as low (that is, low risk of bias for all
domains), high (that is, high risk of bias for one or more
domains), or unclear (that is, unclear risk of bias for one or more
domains in the absence of high risk of bias). We extracted data
from the original reports of trials for the first collection of
meta-analyses (in duplicate for a third of the meta-analyses),
and from the Cochrane reviews for the second collection.
Data synthesis and analysis
Association between trial sample size and
treatment effect
The trials within each meta-analysis were sorted by their sample
size: using quarters within each meta-analysis (from quarter 1
including 25% of the smallest trials, to quarter 4 including 25%
of the largest trials), and using size groups across meta-analyses
(<50, 50-99, 100-199, 200-499, 500-999, and ≥1000 patients).
Treatment effects (measured as odds ratios) were compared
between quarters and size groups by multilevel logistic
regression models with random effects.11 These hierarchical
models allowed for taking into account random intervention
effects (between trial heterogeneity) within meta-analyses as
well as random variation in the effect of trial sample size
between meta-analyses. The results were expressed as average
ratios of odds ratios. This measure is the ratio of the odds ratio
in smaller trials to the odds ratio in larger trials. A ratio of odds
ratios less than 1 indicates larger estimates of the treatment
effect in smaller trials. The heterogeneity across meta-analyses
was quantified with τ2, the variance between meta-analyses. We
performed tests for linear trend across quarters and size groups.
Sensitivity analyses
We reassessed the influence of trial sample size on treatment
effect estimates by comparing treatment effects between trials
by quarters (quarter 1 v quarters 2-4; quarters 1 and 2 v quarters
3 and 4; quarters 1-3 v quarter 4) and by fixed thresholds for
trial sample size (50, 100, 200, 500, and 1000 patients; for
example, for the 200 patient threshold, we compared treatment
effects between trials with less than 200 patients and trials with
200 patients or more). We used the two stage approach to
meta-epidemiological analyses as described by Sterne and
colleagues12 and further adjusted these analyses for the following
trial characteristics: domains of risk of bias,13-17 overall risk of
bias, centre status,8 18 and time since publication of the first trial
within each meta-analysis.
Web appendix 2 details the statistical methods. We used SAS
version 9.2 (SAS) for the multilevel models and Stata MP
version 10.0 (Stata Corp) for the meta-epidemiological analyses.
Results
The study sample included 93 meta-analyses (735 randomised
controlled trials; web appendix 3). A median of seven trials
(range 3-30) were included per meta-analysis. Trial sample size
varied greatly among the meta-analyses (median 34-2371
patients) and within the meta-analyses (for example, trial sample
size ranged from 106 to 48 835 patients in one meta-analysis).
Association of trial sample size and treatment
effect
Treatment effect estimates were significantly larger in smaller
trials regardless of the sample size. Compared with trials in
quarter 4 (which included the largest trials), treatment effects
were, on average, 32% larger in trials in quarter 1 (which
included the smallest trials; ratio of odds ratios 0.68, 95%
confidence interval 0.57 to 0.82), 17% larger in trials in quarter
2 (0.83, 0.75 to 0.91), and 12% larger in trials in quarter 3 (0.88,
0.82 to 0.95). Heterogeneity across meta-analyses ranged from
small to moderate in the three comparisons (τ2=0.30, 0.07, and
0.02, respectively; fig 1⇓).
Compared with trials of 1000 patients or more, treatment effects
were, on average, 48% larger in trials with fewer than 50 patients
(ratio of odds ratios 0.52, 0.41 to 0.66), 34% larger in trials with
50-99 patients (0.66, 0.56 to 0.79), 30% larger in trials with
100-199 patients (0.70, 0.61 to 0.80), 19% larger in trials with
200-499 patients (0.81, 0.73 to 0.88), and 10% larger in trials
with 500-999 patients (0.90, 0.82 to 1.00; fig 1). Heterogeneity
across meta-analyses was moderate (τ2 ranged from 0.11 to
0.26).
For both analyses, ratios of odds ratios showed a significant
linear trend (both P<0.001).
Sensitivity analyses
In the two stage meta-epidemiological analyses, treatment effect
estimates were, on average, 23% larger in quarter 1 trials (that
is, the smallest trials) than in the other trials (ratio of odds ratios
0.77, 95% confidence interval 0.65 to 0.91), 19% larger in
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2013;346:f2304 doi: 10.1136/bmj.f2304 (Published 24 April 2013) Page 2 of 5
RESEARCH
quarter 1 and 2 trials than in quarter 3 and 4 trials (0.81, 0.74
to 0.88), and 15% larger in quarter 1-3 trials than in quarter 4
trials (that is, the largest trials; 0.85, 0.79 to 0.90). With
comparisons of fixed thresholds of sample size, treatment effect
estimates were also significantly larger in smaller trials,
regardless of the threshold level. The heterogeneity across
meta-analyses was low for all analyses (fig 2⇓). Results were
consistent after adjustment on the following trial characteristics:
domains of risk of bias, overall risk of bias, centre status, and
time of publication since the first trial (web appendix 4).
Discussion
In this meta-epidemiological study of 93 meta-analyses of 735
trials, we found significantly larger estimates of treatment effects
in smaller trials, regardless of sample size. Treatment effect
estimates differed within meta-analyses solely based on trial
sample size, with, on average, stronger estimates in small to
moderately sized trials than in the largest trials. The average
difference was substantial and ranged from 12% to 32% when
comparing estimates between quarters of sample size within
meta-analyses.
Strengths and weaknesses of the study
Our results were based on a large meta-epidemiological study
of 93 meta-analyses, representing various medical areas
published in the leading journals of each medical speciality or
in the Cochrane Database of Systematic Reviews. Cochrane
reviews have generally been shown to be of higher
methodological quality, are better reported, and have fewer
conflicts of interest than do non-Cochrane reviews.19-21 To
explore the influence of sample size on treatment effect, we
used several complementary approaches, which all showed
consistent results. However, because our results were based on
meta-analyses of trials assessing binary outcomes, they cannot
be extrapolated to trials assessing continuous outcomes because
such trials usually differ in medical condition, risk of bias,
sample size, and statistical analysis.
Possible explanations
Several mechanisms could help explain the association between
trial sample size and treatment effects regardless of sample size.
The first may be related to reporting bias. Smaller studies are
more prone to publication bias,5 defined by the tendency for
more likely publication of reports of studies with significant
than non-significant results.22 A continuum of publication bias
could exist to some extent: the larger the trial, the greater the
probability that results are published, regardless of statistical
significance. Smaller trials might also bemore prone to outcome
reporting bias.23 24
Another possible mechanism is the difference in methodological
quality by sample size.25Our results tended to be consistent after
adjustment on domains of risk of bias, as well as overall risk of
bias. Finally, it is possible that the larger the sample size, the
greater the heterogeneity in selecting participants26 or
implementing interventions. Future research is needed to explore
the effect of these different mechanisms.
Implications for researchers
Our results have an important effect on the interpretation of
results of clinical trials and meta-analyses in general. The main
issue of systematic reviews and meta-analyses is whether the
combined treatment effect estimated by synthesising all included
studies provides the best estimate of the true treatment effect,
or whether the studies overestimate or underestimate the
treatment effect.27 Because larger trials28 are probably more
pragmatic than smaller trials, with wider eligibility criteria26
and greater variability in interventions, treatment effect estimates
reported in large trials could be closer to the true treatment effect
in real life. Thus, meta-analyses of all available
evidence—whatever the trial sample size—might not reflect
the true treatment effect.
Several authors have suggested that the results from large
randomised controlled trials are inherently superior to those
from smaller trials, even when the results of smaller trials are
pooled in a meta-analysis,29 30 and that an substantially large
trial should be conducted to definitively answer the question
across a large sample of the population. Glasziou and
colleagues31 also proposed relying on the results of the most
precise trial if a meta-analysis was not available. Our results
raise questions about whether the meta-analysis should be
restricted to larger trials (or even to the “largest” trial). The
downside of this approach would be imprecise estimates of the
treatment effect. Rücker and colleagues recently proposed a
method of limit meta-analysis, which allows for predicting
treatment effects when the precision of each trial is increased
to infinity.32 33 This approach is close to the regression based
model described by Moreno and colleagues.34
Conclusions
With a large meta-epidemiological study, we found smaller
trials to have significantly larger estimates of treatment effects,
regardless of sample size. Effect estimates differed within
meta-analyses solely based on trial sample size, with, on
average, stronger effect estimates in small to moderately sized
trials than in the largest trials. These stronger effects might not
reflect the true treatment effect; therefore, robustness of the
conclusions of a meta-analysis, including assessment of the
influence of trial sample size on treatment effect estimates using
sensitivity analyses (for example, subgroup analyses comparing
quarters or limit meta-analysis), should be assessed. Reviewers
and readers can easily check whether the result for the overall
meta-analysis agrees with the results for the largest trials (that
is, those in quarter 4 of sample size). Interpretation of the pooled
result should be cautioned when this is not the case. More
generally, our results raise questions about how meta-analyses
are currently performed, especially whether all available
evidence should be included in meta-analyses because it could
lead to more beneficial results.
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What is already known on this topic
Sample size varies greatly among trials, ranging from tens of patients to thousands of patients, even within one meta-analysis answering
the same question
Small study effect has been previously defined as the tendency for small trials in a meta-analysis to show larger treatment benefits
The concept of using a single threshold to distinguish small and large trials, whatever the medical area or intervention being tested, is
not straightforward
What this study adds
Smaller trials had significantly larger estimates of treatment effect, regardless of sample size.
Effect estimates differed within meta-analyses solely based on trial sample size, with, on average, stronger estimates seen in small to
moderately sized trials than in the largest trials
The robustness of the conclusions of a meta-analysis should be assessed with careful interpretation of results if the overall result is not
consistent with those of the largest trials
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Figures
Fig 1 Comparison of treatment effect estimates between trial sample sizes, grouped by quarters (from quarter 1 with the
smallest trials, to quarter 4 with the largest trials) and by size groups (from <50 patients to ≥1000 patients). Both analyses
included all 93 individual meta-analyses (735 randomised controlled trials)
Fig 2 Comparison of treatment effect estimates between trial sample sizes grouped by quarters (from quarter 1 with the
smallest trials, to quarter 4 with the largest trials) and by fixed thresholds (according to numbers of patients). All 93
meta-analyses did not contribute to the analysis, depending on the threshold used (at least one trial with a sample size less
and more than the threshold within each meta-analysis was required to perform these analyses). *Five meta-analyses did
not contribute to the analysis (three included fewer than four trials; for two trials, the meta-regression model did not converge,
therefore, the ratio of odds ratios could not be obtained). †One meta-analysis did not contribute to the analysis (the
meta-regression model did not converge, therefore, the ratio of odds ratios could not be obtained)
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